BPP is engaged on a scheme by GW Pharmaceuticals on a large scale production and processing facility in the South East of England. This plant will be integrating science and development of cannabidiol medicine. GW Pharmaceuticals are global leaders in developing cannabinoid-based medicines. Their lead product, approved in the US and undergoing approval in the EU, is designed to treat rare and severe forms of childhood-onset epilepsy, potentially offering relief to patients for conditions that previously had few treatment options.
The design, now concluded, was undertaken by Austin UK using BIM 3D modelling. Construction started for the new multimillion pound facility in October 2017 and the interior fit-out in May 2018.
BPP provided construction cost audit services on this project.